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AbstrACt
Purpose Biliary atresia can easily be screened using 
a stool colour card (SCC) and has shown to significantly 
reduce time to diagnosis, improving children’s outcome. 
Despite the general approval of the clinical usefulness 
of the SCC, physicians remain reluctant: it might 
unnecessarily worry parents. This study aimed to analyse 
the parental reaction to this screening method and if it 
evokes parental stress.
Methods A semistructured questionnaire was sent to 
parents with one or more healthy child to inquire about 
reactions on receipt and use of the SCC.
results 109/256 questionnaires were returned and 
evaluated (43%). 107/107 parents considered the SCC 
as helpful, a simple screening method and easy to use 
(100%). 26/43 were reassured when receiving the SCC 
(60%), 2 were worried (5%) and 9 had no particular 
feelings (21%). In 41/49, emotions experienced during its 
use were positive or neutral (84%), and 3 were worried 
(6%). In 41/50, the discussion with the paediatrician about 
stool colour-linked pathologies was neutral (82%), and 9 
felt uneasy (18%).
Conclusion A vast majority of parents appreciate 
the SCC. It creates uneasiness in a minority of parents. 
Our results are encouraging and argue in favour of 
implementing the regular distribution of the SCC in 
antenatal, postnatal and newborn infant clinics.
IntroduCtIon
Biliary atresia is a rare pathology in 
newborns.1 It leads to the obstruction of the 
biliary tree, inducing neonatal cholestasis 
and biliary cirrhosis, leading to death in the 
first years of life if untreated.1 In Europe, 
biliary atresia affects between 1/14 000 and 
1/20 000 live births; in Switzerland, the 
incidence is of 1/17 800 live births.2 The 
diagnosis is suspected in case of persistent 
jaundice, along with discoloured stools, dark-
yellow urine and hepatomegaly.3–5 The treat-
ment of biliary atresia consists of the Kasai 
hepato-porto-enterostomy, aiming to restore 
bile flow,1 followed by liver transplantation if 
cirrhosis progresses. Biliary atresia is the most 
frequent indication for liver transplantations 
in children.6 
The median age for the Kasai procedure 
in Switzerland is late 68 days.2 Serinet et al 
observed, in a study of 695 patients who had 
undergone a Kasai procedure, that the earlier 
the operation was performed, the better was 
the survival rate of children with their native 
livers.7 Consequently, in order to avoid early 
liver transplantation, a neonatal screening 
is needed to allow for timely diagnosis of 
biliary atresia, so that the surgical treatment 
can be performed the earliest possible. Many 
screening programmes for biliary atresia have 
been proposed, such as measuring of serum 
bile acid,8 serum direct bilirubin,9 urinary 
sulfated bile acid,10 and faecal bilirubin and 
fat11; however, they have not been put into 
practice extensively. Yet, an easy method, 
which detects neonatal cholestasis in a simple 
way, and in particular biliary atresia, is to 
look at the baby’s stool colour, pale in cases 
of cholestasis, that is, grey, cream or white, 
occasionally pigmented as a light caramel 
colour.12 Thus, a screening programme with 
a stool colour card (SCC), showing different 
normal and abnormal stool colours, to be 
What is known about the subject?
 ► Screening with a stool colour card is a cost-effective 
and simple screening method for biliary atresia.
 ► Screening with a stool colour card helps to diagnose 
early biliary atresia.
 ► Concerns regarding parental anxiety are thought to 
be the reason why some Swiss physicians do not 
use the stool colour card.
What this study hopes to add?
 ► A vast majority of parents appreciate the stool colour 
card for the screening of biliary atresia.
 ► It creates uneasiness in a minority of parents.
 ► Our results are encouraging and argue in favour of 
implementing the regular distribution of the stool co-
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compared with the baby’s stool, was first introduced in 
Japan in 198713 and in 2002 in Taiwan.5 This has led to 
a significant reduction in late biliary atresia diagnoses, 
has allowed for significantly earlier Kasai operations, 
increased the jaundice clearance rate at 3 months after 
surgery, thus reducing the need for hazardous liver trans-
plantation at a young age.14 The screening for biliary 
atresia or obstructive cholestasis with a SCC is increasingly 
used in Europe. In Germany, its use has become compul-
sory in 2016. In Switzerland, the card has been available 
for optional distribution since 2009.15 The Swiss SCC is 
an A5 formatted hard paper card and shows four normal 
and three pathological babies’ stool colours (figure 1, 
see also www. basca. ch). It is handed out at birth or at 
4 weeks of life at the first appointment with the paedi-
atrician. If an abnormal stool colour is observed, the 
paediatrician is thought to either immediately contact a 
paediatric gastroenterologist, or the Swiss Pediatric Liver 
Center in Geneva, for further advice. The parents also 
have the possibility to directly reach the Geneva Centre 
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by email (link on the website). Since Switzerland is a 
small country, this process is feasible and prevents time 
loss in the process of the so much sought early diagnosis 
of biliary atresia.
Paediatricians’ reactions to the introduction of the 
SCC are substantial. Despite the general approval of 
the usefulness of the SCC, physicians remain reluctant 
to the definitive and nationwide implementation of this 
screening method. Some healthcare providers consider 
that the distribution of the SCC might unnecessarily 
worry parents and add unnecessary consultations. The 
aim of this study was to analyse and clarify the parental 
reaction to the SCC in Switzerland.
Patients and methods
A semistructured questionnaire was designed for parents 
to assess the SCC’s handiness of use, and what feelings 
its receipt and use triggered (box 1). Between 2013 and 
2016, 256 questionnaires were distributed to parents with 
at least one child in three different parts of Switzerland 
(Italian, German and French-speaking). The distributed 
envelopes contained an introduction letter addressed 
to parents, the questionnaire, the SCC and a stamped, 
addressed envelope to return the questionnaire. All 
documents were written in the three languages.
The reported percentages were calculated according to 
the number of answers obtained per question. No statis-
tics were performed, the results being simply descriptive.
results
descriptive results
A total of 109/256 (43%) questionnaires were returned 
and evaluated. There was a difference between the 
language regions from where the questionnaires 
were returned: the participants responding from Ital-
ian-speaking Switzerland returned 48/50 (96%) of 
questionnaires, from the German-speaking Switzerland 
20/100 (20%) were returned and from the French-
speaking 41/106 (39%). Twenty-three parents (21%) 
used the card in ‘real-time’, that is, with their just born 
baby; the remainders used the card after their stay at the 
maternity clinic. Forty parents (37%) used the card with 
their first baby. Most parents wished to receive the SCC 
at the maternity clinic (85/106, 80%); the remainders 
preferred to receive it after having left the clinic, either 
by their paediatrician or their midwife. Most parents 
(98/100, 98%) had never heard about biliary atresia 
before receiving the SCC.
Parents’ reaction to the sCC
As to the SCC’s user-friendliness, 100% (107/107) of 
parents found it either ‘very’ easy to use (69/107, 64%) 
or ‘quite’ easy to use (38/107, 36%). The written expla-
nations on the SCC regarding the screening were consid-
ered to be clear (105/108, 97%). The majority of parents 
needed no further explanations from their paediatrician 
(90/93, 97%). The colours on the card were considered 
appropriate in 98% (103/105). The majority of parents 
had no difficulty in identifying the matching colour 
(93/103, 90%).
When receiving the SCC, 60% (26/43) of parents were 
reassured, 21% (9/43) had no particular feelings and 5% 
(2/43) were worried (figure 2).
Emotions experienced during the use of the SCC 
were in 84% (41/49) positive or neutral; 6% (3/49) of 
parents were worried when using the SCC (figure 2). For 
both questions (receipt and use), multiple answers were 
possible. When analysing the subgroup of parents using 
the SCC with their very newborn in the maternity clinic, 
they were clearly not worried at all (0/19 worried), and 
100% (19/19) were reassured, surprised or indifferent 
when using it.
The conversation later on with the paediatrician about 
pathologies linked to the stool colour was not a source 
of concern in 82% (41/50) of parents; 18% (9/50) 
box 1 Questionnaire
 ► How many children do you have? How old are they?
 ► Do you know a baby’s normal stool colour?
 ► Do you know the stool colour card (card which shows the normal 
and abnormal stool colours)?
 ► Do you know the disease called ‘biliary atresia’?
 ► Did you receive a stool colour card for your baby?
 – If yes: did you use the card?
 – If no: why not?
 ► If you received the stool colour card:
 – Who did it give to you?
 – When did you receive it?
 – How did you react when you received it?
 ► At what moment do you think parents should receive the stool co-
lour card?
 ► Do you think that the stool colour card is easy to use?
 ► Are the explications on the card clear?
 ► Does the website www.basca.ch give clear information?
 ► Are the stool colours on the card accurate?
 ► Did you find it difficult to choose a colour?
 ► How did you react when your paediatrician discussed with you dis-
eases related to your baby’s stool colour?
 ► How did you react when you used the stool colour card?
 ► Did you have to ask your paediatrician questions (or via the website 
www.basca.ch)?
 ► To what degree do you agree with the following statements?
 – I think the stool colour card is useful.
 – I think the stool colour card is easy to use.
 – I think the stool colour card not necessary.
 – I think that the stool colour card can reassure parents.
 – I think that the stool colour card is an easy tool to discover liver 
disease in newborns.
 – I think the stool colour card should be introduced in the baby’s 
health booklet.
 – I think the stool colour card should be introduced in the baby’s 
vaccination record.
 ► What is your general meaning about the stool colour card?
Questionnaire used in this study. All but the last one were questions with a list 










4 Borgeat M, et al. BMJ Paediatrics Open 2018;0:e000269. doi:10.1136/bmjpo-2018-000269
Open Access
expressed that they felt some degree of uneasiness during 
this conversation (figure 3).
The answers to the last question of the questionnaire, 
requiring comments, are not reported in detail, but in 
general commentaries again were positive.
dIsCussIon
It is now established and generally acknowledged that 
the SCC for newborns is a sensitive and specific screening 
method for biliary atresia and consequently improves 
prognosis of those patients by reducing the age when the 
Kasai procedure is performed.5 15 The positive clinical 
effects of the SCC has repeatedly been demonstrated in 
Taiwan from the beginning of the years 2000.5 14 It is now 
also widely accepted that the SCC screening increases 
parents' and physicians' awareness of biliary atresia and 
thus is associated with a decrease of late referrals of 
affected babies.14 After the strong success of the SCC in 
Taiwan, many other countries have developed screening 
and biliary-atresia-awareness-raising programmes. In 
France, a video campaign was initiated in 2014 (http://
www. youtube. com/ watch? v= XsSXmR4u2uM).
In Switzerland, the SCC has been available since 
October 2009 and can be ordered by physicians, mater-
nity clinics and midwives via a website designed for this 
purpose (www. basca. ch). Thus, the Swiss SCC is either 
distributed right after birth, 1 or 2 weeks later, or at the 
baby’s age of 1 month when it is seen for the first time 
by his paediatrician. In our survey, parents felt that the 
best moment to receive the SCC is at the maternity clinic 
and that it should be inserted into the children’s health 
booklet. Indeed, if the SCC is only distributed at the first 
appointment when the baby is 4 weeks old, this may lead 
to delayed diagnosis: a crucial indicator for the diagnosis 
of biliary atresia is the typical shift of the stool colour 
from dark yellow to grey pale over the first weeks of life. 
We must aim to assure that maternity clinics deliver the 
SCC right after childbirth and have the parents repeat-
edly observe their newborns’ stool colour. Consequently, 
the paediatrician will analyse and address, and not intro-
duce, the SCC at the baby’s first appointment.
As for the handiness of the SCC, most parents consid-
ered the stool colours on the card as appropriate and had 
no difficulties in choosing the right shade. However, our 
experience with parents with biliary atresia babies tells us 
that in cases of pale stools, that is, ‘biliary atresia-stools’, 
it might be difficult to choose the right colour due to the 
staining of the baby’s stools by the dark-yellow urine. The 
paediatrician must be aware of this and check the baby’s 
stool himself.
An additional uneasiness of paediatricians is the 
possible time consumption it may create, that the analysis 
and discussion of the SCC may require (too much) time. 
Our study refutes this assumption: most of the parents 
did not need further explanations about the card and its 
content during the time spent with their paediatrician. 
We do believe that the paediatrician, at the first appoint-
ment with his new patient, in any case, is thought to ask 
about the stool and urine colour; the expenditure of 
time thus remains the same, with our without the SCC, 
or, we dare say, might be even less, since the parents are 
prepared to the questions after having used the SCC.
One of the chief objectives of this survey was to evaluate 
the degree of parental concern when receiving and using 
the SCC. The vast majority of parents were, on receipt 
of the card, reassured by or indifferent to the SCC. The 
individual use of the SCC was, in general, not a negative 
or worrisome experience. The conversation with the 
paediatrician pathologies linked to the newborn’s stool 
colour generally did not worry them. But indeed, some 
parents expressed concerns either when receiving (5%) or 
when using (6%) the SCC. Only during the conversation 
later on with the paediatrician about pathologies linked 
to the stool colour more parents, 18%, expressed that 
they felt some degree of uneasiness during this conversa-
tion (4% ‘yes a lot’, 14% ‘yes rather than no’). It seems to 
us that this is a rather ‘normal’ reaction and not clearly 
due to the SCC, since parents naturally often feel uncom-
fortable during a discussion about possible pathologies 
linked to their baby, mirrored by the 14%. Indeed, 4% 
Figure 2 Parent’s reaction when receiving and using the 
stool colour card. Parents were mostly reassured or had 
neutral feelings.
Figure 3 Parent’s reaction during the discussion with the 
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were clearly anxious, which is in line with the numbers 
reported after receiving of the SCC and during its use. 
The 18% of uneasiness are also in agreement with the 
generally reported postnatal anxiety, which is indicated 
to be common: the literature states that up to 18% of 
mothers experience some degree of anxiety in the first 
months after birth, and even more so if the newborn 
is a first-born.16–18 Seen in this context, our results are 
expected and rather reassuring. One of the major factors 
creating anxiety in screening processes is the time period 
awaiting results and/or before seeing a professional to 
be counselled and reassured.19 Importantly and in any 
case of screening, professional backup by midwives or 
paediatricians must be easily accessible. In this partic-
ular screening, parents can also be encouraged to use 
the electronic contact noted on the SCC, which allows 
for direct and ready exchange with the coordinators of 
the Swiss screening centre. Further, it is of utmost impor-
tance to address possible concerns before they appear, and 
the SCC must be introduced with appropriate, concise 
explanations.
This work has some weaknesses. It is a very small study, 
with a little response rate. Thus, we consider it as of 
preliminary—but path breaking—character; the enquiry 
might gain in impact if repeated on a larger scale, for 
example using telephone consultations. Further, there 
were significant differences in the return rate of the ques-
tionnaires depending on the language region. Since we 
omitted to ask for personal details of the responders, we 
are unable to say if this is due to the cultural background 
of the parents or due to the different introduction of the 
questionnaire by the local paediatrician, even more so 
since Switzerland is a very multicultural country in every 
language region.
In conclusion, the vast majority of parents judged the 
SCC as useful, easy to use and being a simple screening 
method. Parents’ concerns when receiving or using the 
SCC were minor. The SCC was not adding unnecessary 
consultations, and the card-related discussion with the 
paediatrician was not a source of anxiety. Our results 
are encouraging and argue in favour of implementing 
the regular distribution of the SCC in antenatal, post-
natal and newborn infant clinics in Switzerland and 
beyond.
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